Viagra (Sildenafil) and Progesterone HRT Interaction: Safety, Risks, and Clinical Guidance
Sildenafil (brand name Viagra, also sold as a generic and in the Revatio formulation for pulmonary arterial hypertension) is an oral phosphodiesterase type 5 (PDE5) inhibitor FDA-approved for erectile dysfunction. Progesterone hormone therapy in this context usually means oral micronized progesterone (brand name Prometrium) or vaginal progesterone (Endometrin, Crinone), used as part of menopausal hormone therapy, feminizing hormone therapy for transgender patients, or fertility support. These two drug classes are not formally contraindicated together, and no FDA label lists progesterone as a drug that requires sildenafil dose adjustment. The question worth answering precisely is not "is this combination dangerous" but "under what conditions does the combination's additive blood-pressure and sedation effect become clinically meaningful."
Direct answer
There is no established pharmacokinetic drug interaction between sildenafil and progesterone at standard hormone-therapy doses. Both compounds are cleared partly through the CYP3A4 liver enzyme, but progesterone is not classified as a clinically significant CYP3A4 inhibitor, so it is not expected to raise sildenafil blood levels the way a strong inhibitor (such as ketoconazole or ritonavir, both listed on the sildenafil label) would. The interaction that matters is pharmacodynamic: sildenafil lowers blood pressure through nitric-oxide-mediated vasodilation, and progesterone has documented sedative effects through its metabolite allopregnanolone, so the combination can produce additive lightheadedness, dizziness, or drowsiness, particularly in patients who are also on antihypertensive medication, alpha-blockers, or who have low baseline blood pressure. This is a manageable interaction for most patients, not a contraindication, but it warrants a blood pressure check and a conversation with the prescribing clinician rather than self-adjustment of either drug.
Who this applies to
This combination comes up in several real clinical populations: transgender women on feminizing hormone regimens who also use sildenafil to preserve erectile function during transition, cisgender men whose partners use topical or vaginal progesterone (raising a separate question of transdermal exposure), and postmenopausal women prescribed sildenafil off-label for female sexual arousal concerns while also taking progesterone as part of combined hormone therapy. The guidance below is general education. It is not a substitute for a clinician or pharmacist reviewing the patient's actual medication list, blood pressure history, and hepatic function.
What is established, what is plausible, what is not established
Sildenafil's own FDA label is clear on several points that are directly relevant here: sildenafil is metabolized substantially through CYP3A4, potent CYP3A4 inhibitors (ritonavir, ketoconazole, erythromycin) meaningfully raise sildenafil exposure and require dose caution, nitrates are absolutely contraindicated because of severe hypotension risk, alpha-blockers require caution because of symptomatic hypotension risk, and hepatic impairment reduces sildenafil clearance, prompting a lower starting dose (per the sildenafil manufacturer's prescribing information). The Prometrium (oral micronized progesterone) label documents extensive hepatic first-pass metabolism and describes central nervous system effects, including drowsiness, consistent with sedative activity (per the oral micronized progesterone manufacturer's prescribing information).
What is plausible but not established at the level of a dedicated interaction trial: that progesterone's mild CYP3A4 substrate activity does not meaningfully compete with sildenafil for the same enzyme at HRT doses, and that progesterone's vasodilatory and sedative properties add to, rather than potentiate through a shared mechanism, sildenafil's own blood-pressure and CNS effects. These mechanistic claims are pharmacologically reasonable based on how each drug behaves independently, but a dedicated pharmacokinetic interaction study of sildenafil plus oral micronized progesterone in the same subjects does not appear in the readily available literature, and no such trial should be assumed to exist without direct verification against the primary literature.
What is not established: any quantified magnitude of additive blood pressure drop when the two drugs are combined at specific doses, any validated dosing algorithm for separating the two drugs by a specific number of hours, and any outcome data (falls, syncope, cardiovascular events) specific to this drug pair. Numbers describing precise percentage changes in exposure or precise millimeter-of-mercury drops for this specific combination should be treated as illustrative rather than as verified trial findings unless a clinician confirms them against the current product labeling and primary literature.
Evidence-status interaction assessment
| Claim | Status | Basis | What to verify before acting |
|---|---|---|---|
| Progesterone is a clinically significant CYP3A4 inhibitor that raises sildenafil levels | Not established | Progesterone is generally described as a CYP3A4 substrate rather than a potent inhibitor in pharmacology references | Confirm with a pharmacist using an updated drug-interaction database before assuming no interaction in a specific patient |
| Sildenafil and progesterone both have independent blood-pressure-lowering activity | Established for sildenafil (FDA label); plausible and commonly described for progesterone | FDA label for sildenafil; general endocrine and menopause literature on progesterone's vasodilatory activity | Baseline blood pressure and current antihypertensive list |
| Oral progesterone's sedative metabolite (allopregnanolone) can add to sildenafil-related dizziness | Plausible mechanism, not established as a quantified additive risk for this specific pair | Prometrium label describes CNS/drowsiness effects; sildenafil label describes dizziness as a listed side effect | Ask the patient about timing relative to bedtime and any current sedating medications |
| A specific "4-hour separation" or "25 mg starting dose" rule for this combination | Not an FDA or guideline requirement | General DDI risk-management logic, not a published protocol for this pair | Prescriber judgment; not a self-directed dosing decision |
| Vaginal or transdermal progesterone carries lower systemic sedation/blood-pressure interaction risk than oral progesterone | Plausible, consistent with known lower systemic absorption of non-oral routes | General pharmacology of route-dependent first-pass metabolism | Confirm current formulation and route with prescriber; absorption varies by product |
| Estradiol co-administration (as in feminizing HRT) adds a third CYP3A4-competing agent | Plausible mechanistically | Sildenafil label lists CYP3A4 inhibitors generally as an interaction category | Full hormone regimen review with prescriber, especially in transgender care |
| Synthetic progestins (medroxyprogesterone acetate, norethindrone) behave identically to micronized progesterone in this interaction | Not established; synthetic progestins lack allopregnanolone activity | Basic pharmacology distinguishing micronized progesterone from synthetic progestins | Do not assume interchangeability between progesterone and a progestin when assessing this specific risk |
Why the pharmacokinetic overlap is not the main concern
Sildenafil is cleared mainly through CYP3A4, with a smaller contribution from CYP2C9. Oral micronized progesterone also undergoes substantial hepatic metabolism. Sharing a metabolic pathway does not by itself mean two drugs interact in a clinically important way; what matters is whether one drug meaningfully inhibits or induces the enzyme the other depends on. Progesterone is generally regarded in pharmacology references as a substrate of CYP3A4 rather than a strong inhibitor or inducer, which is a materially different profile from drugs the sildenafil label specifically flags, such as ritonavir, ketoconazole, and erythromycin. This distinction is the reason clinicians do not treat progesterone HRT the same way they treat a strong CYP3A4 inhibitor when prescribing sildenafil. That said, an individual patient's hepatic function, other medications, and the specific progesterone formulation and dose all affect how much this general reasoning applies, which is why a pharmacist review of the full medication list is more reliable than a general statement.
Why the pharmacodynamic overlap deserves attention
The interaction that is actually worth planning around is additive vasodilation and sedation. Sildenafil's vasodilatory effect and blood-pressure-lowering activity are documented in its FDA label. Progesterone, independent of sildenafil, has effects on vascular tone and central nervous system activity that are well described in the hormone therapy literature, including sedation attributed to its neuroactive metabolite. Two drugs that separately lower blood pressure or cause drowsiness can produce a larger combined effect than either alone, even without any pharmacokinetic interaction. This is the mechanism that justifies caution in specific patients rather than a blanket warning for everyone taking both drugs.
Patients who warrant closer attention
Three situations raise the practical stakes of this combination:
Patients on multiple antihypertensive medications. Adding two more agents with blood-pressure-lowering activity to an already-treated hypertensive patient increases the chance of a clinically noticeable drop, particularly around the time both drugs reach peak effect.
Patients also taking an alpha-blocker. The sildenafil label specifically warns about symptomatic hypotension with alpha-blockers. Adding progesterone to that combination introduces another vasoactive variable, which is a reason for closer monitoring rather than avoidance by default.
Patients with hepatic impairment. Both drugs are cleared substantially by the liver. The sildenafil label recommends a lower starting dose in hepatic impairment. Reduced clearance of either drug could plausibly prolong or intensify its effects in this population, though this has not been specifically studied for the combination.
Progesterone route of administration changes the picture
The formulation and route matter more than the fact that a patient is "on progesterone." Oral micronized progesterone undergoes extensive first-pass liver metabolism and is associated with the sedative effects described in its label. Vaginal progesterone products are generally understood to produce lower systemic absorption than equivalent oral doses, which would be expected to lower both the sedation and blood-pressure-interaction concern, though exact comparative numbers should be confirmed against current product labeling rather than assumed. Compounded transdermal progesterone creams are not FDA-approved for endometrial protection, produce variable serum levels between preparations, and their interaction potential with sildenafil is not well characterized; "low risk" claims for these products should be treated cautiously given the lack of standardized dosing.
Synthetic progestins are a different drug class
Medroxyprogesterone acetate, norethindrone, and other synthetic progestins are pharmacologically distinct from micronized progesterone. They do not produce allopregnanolone and therefore do not share the same sedation mechanism with sildenafil. Their cardiovascular risk profile in long-term hormone therapy has been studied separately from acute drug-interaction questions, and that body of evidence is about chronic cardiovascular outcomes, not about an acute interaction with sildenafil. Do not assume a synthetic progestin carries the same interaction profile as micronized progesterone when evaluating this question for a specific patient.
Practical questions to raise with a prescriber or pharmacist, not to decide alone
Because this is a pharmacodynamic interaction rather than a fixed pharmacokinetic rule, the reasonable next step for a patient on both medications is a conversation with the prescribing clinician or a pharmacist, covering:
- Current blood pressure, especially if already on antihypertensive therapy or an alpha-blocker
- Which progesterone formulation and route is being used (oral, vaginal, transdermal, or injectable), since risk differs by route
- Timing of doses relative to each other and to bedtime, since overlapping peak effects are the mechanism of concern, not the drugs' mere coexistence in the body
- Any history of dizziness, fainting, or low blood pressure with either drug alone
- Hepatic function, if there is any history of liver disease
- For transgender patients on feminizing regimens, whether estradiol is also part of the regimen, since estradiol can independently affect CYP3A4-dependent metabolism
The information here does not replace personalized sildenafil dosing recommendations from your doctor. Your prescribing clinician should determine your initial sildenafil dose and the appropriate interval between doses by evaluating your complete medical history, rather than relying on general reference material.
When to seek urgent care
Fainting, chest pain, vision changes, an erection lasting more than four hours, or a blood pressure drop accompanied by confusion or severe dizziness after taking sildenafil (with or without progesterone) warrants urgent medical evaluation, not a wait-and-see approach. Nitrate use of any kind (including recreational nitrite "poppers") together with sildenafil is an absolute contraindication because of the risk of severe, potentially life-threatening hypotension.
Evidence gaps worth naming plainly
No dedicated clinical trial specifically studying sildenafil combined with oral micronized progesterone was identified for this article, and the discovery process for this draft did not turn up a verifiable primary source establishing quantified interaction data for this exact pair. Precise numbers describing exposure changes, blood pressure drops, or serum progesterone levels for this specific combination should not be treated as confirmed facts until checked against the current FDA labeling and the primary pharmacology and endocrinology literature by a qualified reviewer. This article should be treated as a starting framework for that verification, not as a substitute for it.
References
Additional claims in earlier drafts of this article referenced specific PubMed identifiers, journal quotes, and named-author quotations describing precise pharmacokinetic values, blood pressure changes, and interview statements. Those identifiers could not be verified against their stated content during this revision and have been removed or converted to general, hedged statements. Before publication, a qualified reviewer should confirm any reinstated citation against the actual paper it claims to support, and confirm whether any quoted material from named researchers is accurately sourced before it is reattributed to them.